CN103965291A - Method for preparing octreotide and octreotide acetate - Google Patents

Method for preparing octreotide and octreotide acetate Download PDF

Info

Publication number
CN103965291A
CN103965291A CN201410228795.1A CN201410228795A CN103965291A CN 103965291 A CN103965291 A CN 103965291A CN 201410228795 A CN201410228795 A CN 201410228795A CN 103965291 A CN103965291 A CN 103965291A
Authority
CN
China
Prior art keywords
phase
sostatin
solution
preparation
crude product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201410228795.1A
Other languages
Chinese (zh)
Other versions
CN103965291B (en
Inventor
洪勇
江锡铭
丁金国
黄臻辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Add medicine to the first biochemical pharmaceutcal corporation, Ltd in Shanghai
Original Assignee
Shanghai No1 Biochemical & Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai No1 Biochemical & Pharmaceutical Co Ltd filed Critical Shanghai No1 Biochemical & Pharmaceutical Co Ltd
Priority to CN201410228795.1A priority Critical patent/CN103965291B/en
Publication of CN103965291A publication Critical patent/CN103965291A/en
Application granted granted Critical
Publication of CN103965291B publication Critical patent/CN103965291B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention discloses a method for preparing octreotide and octreotide acetate. The method for preparing octreotide comprises the following steps: sequentially performing reverse phase purification and reverse phase desalination on an octreotide crude product solution by using a high performance liquid reversion phase chromatography method, wherein the packing of the high performance liquid reversion phase chromatography method is a poly styrene-divinyl benzene (PS-DVB) copolymer. The method integrates reverse phase purification and reverse phase desalination, novel application of the copolymer packing, namely, the styrene-divinyl benzene, is designed, and octreotide and octreotide acetate can be prepared in a large scale.

Description

The preparation method of Sostatin, Sostatin acetate
Technical field
The present invention relates to field of biological pharmacy.More specifically, the present invention relates to the preparation method of Sostatin, Sostatin acetate.
Background technology
Angiotensin (or angiotensinamide) is for increasing Cardura, English name angiotensinamide or [Asn 1, Val5] and-angiotensin II, chemical structure is L-Asn-L-Arg-L-Val-L-Tyr-L-Val-L-His-L-Pro-L-Phe, the synthetic polypeptide being made up of eight amino-acid residues, theoretical molecular 1031.18.Hypotension due to when Angiotensin is used for wound or postoperative shock and general anesthesia or lumbar anesthesia etc., can prevent or treat peri-operation period ypotension, as first aid using medicine treatment shock stage ypotension, also can be used for treating angiotensin converting enzyme inhibitor over administration and conventional treatment when invalid.
Pitressin Tannate, the synthetic polypeptide being formed by nine amino-acid residues, its chemical structure is L-Cys-L-Tyr-L-Phe-L-Gln-L-Asn-L-Cys-L-Pro-L-Arg-L-Gly (1 → 6)-disulfide linkage tannate, the theoretical molecular 1084.24 of vassopressin.Pitressin Tannate is antidiuretic hormone medicine, can promote the heavily absorption to moisture of distal renal tubular and collecting tubule and have antidiuretic activity, the clinical diabetes insipidus that is used for the treatment of of its preparation.
Sostatin LAR (Octreotide acetate), by seven amino acid residue and a synthetic polypeptide that Soviet Union's ammonia alcohol forms, chemical structure is D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2R-hydroxyl-1R-(methylol) propyl group]-L-cysteinyl amine ring (2 → 7)-disulfide linkage acetate, the theoretical molecular of Sostatin is 1019.26, and in its bulk drug lyophilized powder, acetic acid content is 5%～12%.Sostatin LAR can suppress tethelin, suppress stomach and intestine pancreas secrete polypeptide etc., the clinical reactivity acromegaly for the long-term RUPTURED ESOPHAGEAL VARICES TREATED WITH OCTREOTIDE of needs of its preparation, the serum growth hormone level that causes as residual in postoperative tethelin increases, the serum growth hormone level that not yet reaches abundant curative effect after hypophysis external radiation exposure radiotherapy raises, and part is not suitable for operative treatment and newly diagnoses growth hormone secreting adenoma patient's preoperative treatment.
The common purification process of polypeptide drugs that gone on the market at present has mostly adopted preparative high performance liquid chromatography, and this method is the effective means that obtains high purity polypeptide target molecule, is also the technical way of our solid phase synthesis Angiotensin purifying and desalination.General polypeptide drugs purification technological design is first mesolow chromatograph enrichment target polypeptides, then high pressure chromatographic refining, but consider the about 1kD of our target polypeptides Angiotensin molecular weight, without suitable molecular sieve gel post, (its applied sample amount is little, flow velocity is low, treatment capacity is little, is relatively applicable to the desalination that molecular weight is greater than 10kD albumen) or ultra-filtration membrane selection.And in mesolow chromatogram, conventional separation method has molecular sieve chromatography, ion exchange chromatography and hydrophobic interaction chromatography, the particle diameter of the filler of using in these chromatographic processes is not conventionally from tens microns to hundreds of micron etc., void size mostly is not hundreds of nanometer not etc., cannot obtain highly purified target polypeptides.If adopt high eluting salt, post-processed cannot find suitable desalination scheme, and separation and purification effect is also limited, and sample loss is very large, and the rate of recovery is calculated also more complicated, very unfavorable for anti-phase preparation of later stage.Now also lack a kind of method of effectively preparing polypeptide salt bulk drug, therefore still in the urgent need to developing the purifying process of new polypeptide salt.
Summary of the invention
Technical problem to be solved by this invention is the low defect of complicated process of preparation, yield in order to overcome polypeptide salt in prior art, and the preparation method of a peptide species, polypeptide salt is provided.The preparation method of polypeptide salt of the present invention, taking polypeptide as starting raw material, through high pressure reverse-phase chromatography purifying and desalination step, prepares highly purified polypeptide salt, the particularly method of Angiotensin acetate, Pitressin Tannate and Sostatin LAR.
Contriver finds through research repeatedly, and the filler of the classical purifying of high pressure reverse-phase chromatography is silica matrix at present, and its post is imitated, and resolving power is high, but chromatographic condition pH2-7 tolerance is narrower; And Agilent polymer packing PLRP-S is styrene-divinylbenzene (PS-DVB) multipolymer, can tolerate broader pH scope (pH scope can reach 1-14), and available 1M NaOH regeneration of waste liquor, also can precisely control pore size and aperture form, make the accessible diffusion of solute molecule, with respect to silica matrix, it has increased effective surface area, can keep good post effect and resolving power, and promote the volume containing the sample of filler.
The present invention solves the problems of the technologies described above by the following technical programs:
The invention provides the preparation method of a peptide species, it comprises the steps: to adopt high performance liquid phase reverse-phase chromatography that polypeptide crude product solution is carried out to anti-phase purifying, anti-phase desalination successively; The filler of high performance liquid phase reverse-phase chromatography is styrene-divinylbenzene (PS-DVB) multipolymer.
Wherein, described polypeptide crude product can be each peptide species crude product of this area, is preferably basic polypeptide crude product, is more preferably Angiotensin crude product, vassopressin crude product or Sostatin crude product.Described Angiotensin crude product is preferably the synthetic Angiotensin crude product of the disclosed employing solid phase method of patent application CN201210131066.5, and HPLC purity is 80～90%; Described vassopressin crude product is preferably the synthetic vassopressin crude product of the disclosed employing solid phase method of patent application CN201210131067.X, and HPLC purity is 80～90%; Described Sostatin crude product is preferably for adopting the synthetic Sostatin crude product making of solid phase method, and HPLC purity is 80～90%.
Described polypeptide crude product solution is preferably the 10g/L solution that 5% acetonitrile solution forms for polypeptide crude product is dissolved in concentration of volume percent.
Wherein, the condition optimization of described anti-phase purifying is as follows: mobile phase A is that volume percent is 0.1% trifluoroacetic acid aqueous solution, Mobile phase B is that volume percent is 0.1% trifluoroacetic acid acetonitrile solution, moving phase C is described polypeptide crude product solution, flow velocity is 180～220mL/min (being preferably 200mL/min), and detection wavelength is 220nm;
Carry out online loading, wash-out according to the condition of following table, per-cent is volume percent;
Elution step Elution time Elutriant
1 0～2min 95％A+5％B
2 2～22min 100％C
3 22～40min 95％A+5％B
4 40～100min 95％A+5％B→65％A+35％B
5 100～110min 40％A+60％B
6 110～120min 95％A+5％B
The elutriant that collection retention time is 45～95min obtains polypeptide-trifluoroacetic acid solution.
Wherein, the condition optimization of described anti-phase desalination is as follows: mobile phase A is water, and Mobile phase B is acetonitrile, and moving phase C is 0.1mol/L NaOH solution, and flow velocity is 180～220mL/min (being preferably 200mL/min), and detection wavelength is 220nm;
Carry out online loading, wash-out according to the condition of following table, per-cent is volume percent;
Elution step Elution time Elutriant
1 0～5min 95％A+5％B
2 5～45min 75%A+25% polypeptide-trifluoroacetic acid solution
3 45～55min 95％A+5％B
4 55～75min 75％A+5％B+20％C
5 75～95min 95％A+5％B
6 95～155min 95％A+5％B→65％A+35％B
7 155～175min 40％A+60％B
8 175～180min 95％A+5％B
The elutriant that collection retention time is 100～155min can obtain polypeptide solution.
Wherein, the filling condition of described high performance liquid phase reverse-phase chromatography is preferably as follows: filler is Agilent PLRP-S styrene-divinylbenzene (PS-DVB) multipolymer, aperture 10nm, and particle diameter 10 μ m, dress column density 0.33g/mL, post is pressed as 650psi.
The present invention also provides the preparation method of polypeptide salt, and it comprises the steps: that the polypeptide solution that above-mentioned preparation method is obtained mixes with acid.
Wherein, described acid is preferably Glacial acetic acid or tannic acid.
In the present invention, after described mixing finishes, preferably also carry out concentrating under reduced pressure, lyophilize, can obtain polypeptide salt freeze-drying powder.The pressure of described concentrating under reduced pressure is preferably-0.15～-0.05MPa, and the temperature of described concentrating under reduced pressure is preferably 25～35 DEG C.
Wherein, described polypeptide is preferably Angiotensin, vassopressin or Sostatin.
Wherein, described polypeptide salt is preferably Angiotensin acetate, vassopressin tannate or Sostatin acetate.
Angiotensin, vassopressin and Sostatin are all a kind of peptide materials, unstable under alkaline condition, easily degraded, especially under strong alkali environment, integrated survey of the present invention de-concentration and the time of alkali cleaning, to ensure to reduce destruction and the loss of sample in demineralising process.
Innovative point of the present invention is anti-phase purifying and anti-phase desalination coupling, in Angiotensin, contain an alkaline arginine residues (its guanidine base side chain pKa value is 12.48) and an alkaline histidine residues, in vassopressin, contain an alkaline arginine residues, in Sostatin, contain the residue of an alkaline Methionin, this polypeptide is very capable in conjunction with TFA (trifluoroacetic acid) under strong acidic condition, and may there is multiple alkaline residues site can be in conjunction with, need highly basic will in TFA, remove with displacement, for preparation in enormous quantities and desalinating process, design the more recent application of polymer packing PLRP-S.Novelty of the present invention has been used anti-phase absorption method desalination, adopts on-line dilution loading to solve the problem of anti-phase purifying and anti-phase desalination coupling.
Meeting on the basis of this area general knowledge, above-mentioned each optimum condition, can arbitrary combination, obtains the preferred embodiments of the invention.
Agents useful for same of the present invention and raw material be commercially available obtaining all.
Positive progressive effect of the present invention is:
(1) the present invention has utilized the method for acid-base neutralisation, first use in highly basic and strong acid, utilize the hydrophobic binding of polypeptide and reverse phase filler, the free strong acid root of neutral wash-out in chromatographic column, and adopt in Alkaline Elution and the strong acid root of combination, the polypeptide solution of preparation deacidification.
(2) the present invention adopts online loading, without dilute sample solution, and directly biased sample solution and mobile phase A, Mobile phase B in liquid phase systems pipeline, be loaded in chromatographic column, avoided after dilution, sample volume is excessive, the problem that concentration is diluted, is applicable to continuous production.
(3) the present invention has used anti-phase absorption method desalination innovatively, adopts on-line dilution loading to solve the problem of anti-phase purifying and anti-phase desalination coupling, has optimized production technique, and applicable industrialization is produced continuously.
Embodiment
Mode below by embodiment further illustrates the present invention, but does not therefore limit the present invention among described scope of embodiments.The experimental technique of unreceipted actual conditions in the following example, according to ordinary method and condition, or selects according to catalogue.
Embodiment 1 (HPLC method detects Angiotensin crude product raw material and purify intermediates solution purity and quantitative)
Instrument: Waters2695/2489 high performance liquid chromatograph
Separator column: Waters XBridge-C18,4.6 × 150mm, 5 μ m
Moving phase: A is 20mM NaH 2pO 4-H 3pO 4(pH3.0), B is that volume percent is 50% acetonitrile solution
Flow velocity is 1.0mL/min, and detection wavelength is 220nm, and room temperature detects,
Gradient sees the following form shown in 1, and per-cent is volume percent.
Table 1 moving phase gradient
Elution step Elution time Elutriant
1 0～7min 90％A+10％B→60％A+40％B
2 7～13min 60％A+40％B→50％A+50％B
3 13～35min 50％A+50％B→100％B
4 35～40min 100％B
5 40～45min 90％A+10％B
Embodiment 2 (filling of 75mm internal diameter L & L4003 preparative column)
Use Load & Lock dynamic axial compression and static locking technology, filler is styrene-divinylbenzene copolymer (reverse phase filler Agilent PLRP-S), aperture 10nm, particle diameter 10 μ m, dress column density 0.33g/mL, be filled to post bed pressure 650psi, adopt Varian chromatogram loading system, 370g dry powder filler, 2L methyl alcohol stirs after homogenate, pour 75mm internal diameter L & L4003 preparative column into, compression ratio is 3:1, and carrier gas is N 2, regulating nebulizer gas pressure to make oil-pressure gauge pressure is 2000psi, dynamic axial compression is to post bed height 26cm, as anti-phase purifying and anti-phase desalination scheme preparative column used.
Embodiment 3
(1) the anti-phase purifying of Angiotensin crude product raw material
Instrument: Varian SD-1 high-pressure liquid phase preparation system
The preparative column Load & Lock400375 × 260mm of chromatographic column: embodiment 2 self-chamberings, PLRP-S10 μ m10nm
Moving phase: A is that volume percent is 0.1% trifluoroacetic acid aqueous solution, B is that volume percent is 0.1% trifluoroacetic acid acetonitrile solution, Angiotensin crude product (the Angiotensin crude product that the disclosed employing solid phase method of patent application CN201210131066.5 is synthetic) is that dissolution with solvents is mixed with 10g/L solution through the acetonitrile solution of volume percent 5%, filtering the rear sample liquid of clarification is moving phase C, measuring its HPLC purity by the method for embodiment 1 is 84.98%, retention time is 10.34min, and HPLC data are shown in Table 2.
The peak result that table 2 Angiotensin crude product HPLC detects
Peak numbering Retention time (min) Area (microvolt * second) Highly (microvolt) % area
1 5.723 114660 9972 0.68
2 6.470 13557 1592 0.08
3 7.598 9823 899 0.06
4 8.133 76178 7881 0.45
5 8.738 67006 7818 0.40
6 9.088 8971 1327 0.05
7 9.631 46650 4709 0.28
8 10.335 14357014 1242791 84.98
9 10.988 276934 44721 1.64
10 11.138 1118879 118916 6.62
11 11.817 131299 8221 0.78
12 12.251 21447 2115 0.13
13 12.541 30951 3707 0.18
The anti-phase purification condition of the present embodiment is as follows: flow velocity 200mL/min, 220nm detects, purifying gradient sees the following form shown in 3, be that 56.5-62min target main peak is collected as Angiotensin-trifluoroacetic acid solution to retention time, measuring its HPLC purity by the method for embodiment 1 is 98.89%, retention time is 10.51min, and HPLC data see the following form 4.
The gradient (per-cent is volume percent) of the anti-phase purifying of table 3
Elution step Elution time Elutriant
1 0～2min 95％A+5％B
2 2～22min 100％C
3 22～40min 95％A+5％B
4 40～100min 95％A+5％B→65％A+35％B
5 100～110min 40％A+60％B
6 110～120min 95％A+5％B
The peak result that table 4 Angiotensin-trifluoroacetic acid solution HPLC detects
Peak numbering Retention time (min) Area (microvolt * second) Highly (microvolt) % area
1 5.706 3447 360 0.02
2 8.863 7995 949 0.06
3 9.808 14220 1760 0.10
4 10.514 13765923 1133552 98.89
5 11.191 129102 13699 0.93
(2) the anti-phase desalination of Angiotensin-trifluoroacetic acid solution
Instrument: Varian SD-1 high-pressure liquid phase preparation system
The preparative column Load & Lock400375 × 260mm of chromatographic column: embodiment 2 self-chamberings, PLRP-S10 μ m10nm
Moving phase: mobile phase A is pure water, Mobile phase B is acetonitrile, moving phase C is 0.1M NaOH solution, flow velocity 200mL/min, 220nm detects, and the gradient of anti-phase desalination is shown in Table 5, be that 120-132min target main peak is collected as Angiotensin except TFA solution to retention time, measuring its HPLC purity by method in embodiment 1 is 99.51%, and retention time is 10.39min, and HPLC data are in table 6.
The gradient (per-cent is volume percent) that the anti-phase desalination of table 5 is used
Elution step Elution time Elutriant
1 0～5min 95％A+5％B
2 5～45min 75%A+25% Angiotensin-trifluoroacetic acid solution
3 45～55min 95％A+5％B
4 55～75min 75％A+5％B+20％C
5 75～95min 95％A+5％B
6 95～155min 95％A+5％B→65％A+35％B
7 155～175min 40％A+60％B
8 175～180min 95％A+5％B
The peak result that table 6 Angiotensin detects except TFA Solution H PLC
Peak numbering Retention time (min) Area (microvolt * second) Highly (microvolt) % area
1 8.799 11184 1521 0.05
2 9.730 3823 557 0.02
3 10.387 22413365 1987946 99.51
4 11.098 36099 4959 0.16
5 11.326 53415 7451 0.24
6 11.750 6245 657 0.03
Embodiment 4 (Angiotensin salify, concentrated and freeze-drying)
The Angiotensin that embodiment 3 is obtained is except TFA solution 1L, add 2mL Glacial acetic acid, obtain Angiotensin acetate solution,-0.1MPa, the concentrated part acetonitrile of removing in solution of decompression rotation under 30 DEG C of conditions, be distributed in stainless steel pallet, liquid surface height controlling is at 0.5～1.0cm, covering gauze sends into vacuum freeze drier (LYO-1 of Shanghai Tofflon Science and Technology Co., Ltd.) and carries out lyophilize according to pre-designed freeze-drying curve, obtain Angiotensin acetate lyophilized powder solid 13.3g through lyophilize, by feeding intake, 40g Angiotensin crude product calculated yield is 33.2%, measuring its HPLC purity by the method for embodiment 1 is 99.18%, retention time is 10.53min, HPLC data are shown in Table 7.
The peak result that the HPLC of table 7 Angiotensin acetate lyophilized powder detects
Peak numbering Retention time (min) Area (microvolt * second) Highly (microvolt) % area
1 8.864 7464 921 0.06
2 10.529 11398620 1121376 99.18
3 11.176 23762 2733 0.21
4 11.406 51069 5939 0.44
5 11.797 11452 642 0.10
Embodiment 5 (Angiotensin acetate mass spectrometric detection)
Adopt waters micromass ZQ substance level Four bar electrospray ionization mass spectrum (ESI-MS) to measure Angiotensin acetate molecular weight analyte, result shows molecular mass peak [M+1] +measured value 1031.93, leading ion fragment peak [M+2] 2+measured value 516.65, all meets theoretical value 1031.18.
Embodiment 6 (in ion-chromatographic determination Angiotensin acetate sample, acetic acid content and TFA are residual)
Instrument: U.S. Dionex500 ion chromatograph
Separator column: IonPacAS 14-AG 14
Detection mode: electricity is led
Leacheate: 1.0mM NaHCO 3+ 3.0mM Na 2cO 3
Sample thief 100mg crosses DionexOnGuard II RP pre-treatment pre-column after adding 10mL leacheate to dissolve, enter ion chromatograph detection level.Detected result demonstration, acetic acid content is 9.35% (mass percent), TFA content is not for detecting (detectability 5 μ g/g).
Embodiment 7 (HPLC method detects vassopressin crude product raw material and purify intermediates solution purity)
Instrument: Waters2695/2489 high performance liquid chromatograph
Separator column: Agilent XDB-C184.6 × 250mm, 5 μ m
Moving phase: A is that volume percent is the 0.1%TFA aqueous solution, and B is that volume percent is the acetonitrile solution of 0.1%TFA-50%
Flow velocity is 1.0mL/min, and detection wavelength is 214nm, and room temperature detects,
Gradient sees the following form shown in 8, and per-cent is volume percent.
Table 8 moving phase gradient
Elution step Elution time Elutriant
1 0～5min 95％A+5％B
2 5～25min 95％A+5％B→50％A+50％B
3 25～30min 100％B
4 30～35min 95％A+5％B
Embodiment 8
(1) the anti-phase purifying of vassopressin crude product raw material
Instrument: Varian SD-1 high-pressure liquid phase preparation system
The preparative column Load & Lock400375 × 260mm of chromatographic column: embodiment 2 self-chamberings, PLRP-S10 μ m10nm
Moving phase: A is that volume percent is 0.1% trifluoroacetic acid aqueous solution, B is that volume percent is 0.1% trifluoroacetic acid acetonitrile solution, vassopressin crude product (the vassopressin crude product that the disclosed employing solid phase method of patent application CN201210131067.X is synthetic) is that dissolution with solvents is mixed with 10g/L solution through the acetonitrile solution of volume percent 5%, filtering the rear sample liquid of clarification is moving phase C, measuring its HPLC purity by the method for embodiment 7 is 88.13%, and retention time is 14.40min.
The anti-phase purification condition of the present embodiment is as follows: flow velocity 200mL/min, 220nm detects, purifying gradient sees the following form shown in 9, be that 48-54min target main peak is collected as vassopressin-trifluoroacetic acid solution to retention time, measuring its HPLC purity by the method for embodiment 7 is 99.19%, and retention time is 14.60min.
The gradient (per-cent is volume percent) of the anti-phase purifying of table 9
Elution step Elution time Elutriant
1 0～2min 95％A+5％B
2 2～22min 100％C
3 22～40min 95％A+5％B
4 40～100min 95％A+5％B→65％A+35％B
5 100～110min 40％A+60％B
6 110～120min 95％A+5％B
(2) the anti-phase desalination of vassopressin-trifluoroacetic acid solution
Instrument: Varian SD-1 high-pressure liquid phase preparation system
The preparative column Load & Lock400375 × 260mm of chromatographic column: embodiment 2 self-chamberings, PLRP-S10 μ m10nm
Moving phase: mobile phase A is pure water, Mobile phase B is acetonitrile, moving phase C is 0.1M NaOH solution, flow velocity 200mL/min, 220nm detects, and the gradient of anti-phase desalination sees the following form shown in 10, is that 102-112min target main peak is collected as vassopressin except TFA solution to retention time, measuring its HPLC purity by method in embodiment 7 is 99.81%, and retention time is 14.51min.
The gradient (per-cent is volume percent) that the anti-phase desalination of table 10 is used
Elution step Elution time Elutriant
1 0～5min 95％A+5％B
2 5～45min 75%A+25% vassopressin-trifluoroacetic acid solution
3 45～55min 95％A+5％B
4 55～75min 75％A+5％B+20％C
5 75～95min 95％A+5％B
6 95～155min 95％A+5％B→65％A+35％B
7 155～175min 40％A+60％B
8 175～180min 95％A+5％B
Adopt waters micromass ZQ substance level Four bar electrospray ionization mass spectrum (ESI-MS) to measure its molecular mass peak [M+1] +measured value 1084.40, leading ion fragment peak [M+2] 2+measured value 542.75, all meets theoretical value 1084.24.Record vassopressin except TFA content in TFA solution is not for detecting (detectability 5 μ g/g) by embodiment 6.
Embodiment 9 (vassopressin salify, concentrated and freeze-drying)
The vassopressin that embodiment 8 is obtained is except TFA solution 1L,-0.1MPa, the concentrated part acetonitrile of removing in solution of decompression rotation under 30 DEG C of conditions, slowly adding mass volume ratio is 20% tannic acid aqueous solution, tannic acid consumption adds one gram of tannic acid by each ten thousand unit vassopressin, limit adds stirring, obtain vassopressin tannate solution, be distributed in stainless steel pallet, liquid surface height controlling is at 0.5～1.0cm, covering gauze sends into vacuum freeze drier (LYO-1 of Shanghai Tofflon Science and Technology Co., Ltd.) and carries out lyophilize according to pre-designed freeze-drying curve, obtain Pitressin Tannate lyophilized powder solid 10.2g through lyophilize, by feeding intake, 40g vassopressin crude product calculated yield is 25.5%.
Embodiment 10 (HPLC method detects Sostatin crude product raw material and purify intermediates solution purity)
Instrument: Waters2695/2489 high performance liquid chromatograph
Separator column: Kromasil100-3.5C18column4.6 × 100mm
Moving phase: A is 10% Tetramethylammonium hydroxide: water: the aqueous solution that acetonitrile volume percent is 2:88:10, B is 10% Tetramethylammonium hydroxide: water: the aqueous solution that acetonitrile volume percent is 2:38:60.
Flow velocity is 0.8mL/min, and detection wavelength is 210nm, and room temperature detects,
Gradient sees the following form shown in 11, and per-cent is volume percent.
Table 11 moving phase gradient
Elution step Elution time Elutriant
1 0～30min 73％A+27％B
2 30～31min 73％A+27％B→55％A+45％B
3 31～37min 73％A+27％B
Embodiment 11
(1) the anti-phase purifying of Sostatin crude product raw material
Instrument: Varian SD-1 high-pressure liquid phase preparation system
The preparative column Load & Lock400375 × 260mm of chromatographic column: embodiment 2 self-chamberings, PLRP-S10 μ m10nm
Moving phase: A is that volume percent is 0.1% trifluoroacetic acid aqueous solution, B is that volume percent is 0.1% trifluoroacetic acid acetonitrile solution, Sostatin crude product (adopting solid phase method to synthesize makes) is that dissolution with solvents is mixed with 10g/L solution through the acetonitrile solution of volume percent 5%, filtering the rear sample liquid of clarification is moving phase C, measuring its HPLC purity by the method for embodiment 10 is 85.13%, and retention time is 8.59min.
The anti-phase purification condition of the present embodiment is as follows: flow velocity 200mL/min, 220nm detects, purifying gradient sees the following form shown in 12, be that 86-92min target main peak is collected as Sostatin-trifluoroacetic acid solution to retention time, measuring its HPLC purity by the method for embodiment 10 is 99.49%, and retention time is 8.66min.
The gradient (per-cent is volume percent) of the anti-phase purifying of table 12
Elution step Elution time Elutriant
1 0～2min 95％A+5％B
2 2～22min 100％C
3 22～40min 95％A+5％B
4 40～100min 95％A+5％B→65％A+35％B
5 100～110min 40％A+60％B
6 110～120min 95％A+5％B
(2) the anti-phase desalination of Sostatin-trifluoroacetic acid solution
Instrument: Varian SD-1 high-pressure liquid phase preparation system
The preparative column Load & Lock400375 × 260mm of chromatographic column: embodiment 2 self-chamberings, PLRP-S10 μ m10nm
Moving phase: mobile phase A is pure water, Mobile phase B is acetonitrile, moving phase C is 0.1M NaOH solution, flow velocity 200mL/min, 220nm detects, and the gradient of anti-phase desalination is shown in Table 13, and is that 142-152min target main peak is collected as Sostatin except TFA solution to retention time, measuring its HPLC purity by method in embodiment 10 is 99.91%, and retention time is 8.62min.
The gradient (per-cent is volume percent) that the anti-phase desalination of table 13 is used
Elution step Elution time Elutriant
1 0～5min 95％A+5％B
2 5～45min 75%A+25% Sostatin-trifluoroacetic acid solution
3 45～55min 95％A+5％B
4 55～75min 75％A+5％B+20％C
5 75～95min 95％A+5％B
6 95～155min 95％A+5％B→65％A+35％B
7 155～175min 40％A+60％B
8 175～180min 95％A+5％B
Embodiment 12 (Sostatin salify, concentrated and freeze-drying)
The Sostatin that embodiment 11 is obtained is except TFA solution 1L, add 2mL Glacial acetic acid, obtain Sostatin acetate solution,-0.1MPa, the concentrated part acetonitrile of removing in solution of decompression rotation under 30 DEG C of conditions, be distributed in stainless steel pallet, liquid surface height controlling is at 0.5～1.0cm, covering gauze sends into vacuum freeze drier (LYO-1 of Shanghai Tofflon Science and Technology Co., Ltd.) and carries out lyophilize according to pre-designed freeze-drying curve, obtain Sostatin LAR lyophilized powder solid 12.3g through lyophilize, by feeding intake, 40g Sostatin crude product calculated yield is 30.8%, measuring its HPLC purity by the method for embodiment 10 is 99.68%, retention time is 8.60min.Adopt waters micromass ZQ substance level Four bar electrospray ionization mass spectrum (ESI-MS) to measure its molecular mass peak [M+1] +measured value 1019.86, leading ion fragment peak [M+2] 2+measured value 510.67, all meets theoretical value 1019.26.Detect Sostatin LAR lyophilized powder result by embodiment 6 and show, acetic acid content is 8.35% (mass percent), and TFA content is not for detecting (detectability 5 μ g/g).

Claims (11)

1. a preparation method for Sostatin, it comprises the steps: to adopt high performance liquid phase reverse-phase chromatography that Sostatin crude product solution is carried out to anti-phase purifying, anti-phase desalination successively; The filler of high performance liquid phase reverse-phase chromatography is styrene diethylene benzene copoly mer.
2. preparation method as claimed in claim 1, is characterized in that, described Sostatin crude product is to adopt the synthetic Sostatin crude product making of solid phase method, and the HPLC purity of described Sostatin crude product is 80～90%.
3. preparation method as claimed in claim 1, is characterized in that, described Sostatin crude product solution is that to be dissolved in concentration of volume percent be the 10g/L solution that 5% acetonitrile solution forms to Sostatin crude product.
4. preparation method as claimed in claim 1, it is characterized in that, the condition of described anti-phase purifying is as follows: mobile phase A is that volume percent is 0.1% trifluoroacetic acid aqueous solution, Mobile phase B is that volume percent is 0.1% trifluoroacetic acid acetonitrile solution, moving phase C is described Sostatin crude product solution, flow velocity is 180～220mL/min, and detection wavelength is 220nm;
Carry out online loading, wash-out according to the condition of following table, per-cent is volume percent;
Elution step Elution time Elutriant 1 0～2min 95％A+5％B 2 2～22min 100％C 3 22～40min 95％A+5％B 4 40～100min 95％A+5％B→65％A+35％B 5 100～110min 40％A+60％B 6 110～120min 95％A+5％B
The elutriant that collection retention time is 45～95min obtains Sostatin-trifluoroacetic acid solution.
5. preparation method as claimed in claim 4, is characterized in that, the condition of described anti-phase desalination is as follows: mobile phase A is water, and Mobile phase B is acetonitrile, and moving phase C is 0.1mol/L NaOH solution, and flow velocity is 180～220mL/min, and detection wavelength is 220nm;
Carry out online loading, wash-out according to the condition of following table, per-cent is volume percent;
Elution step Elution time Elutriant
1 0～5min 95％A+5％B 2 5～45min 75%A+25% Sostatin-trifluoroacetic acid solution 3 45～55min 95％A+5％B 4 55～75min 75％A+5％B+20％C 5 75～95min 95％A+5％B 6 95～155min 95％A+5％B→65％A+35％B 7 155～175min 40％A+60％B 8 175～180min 95％A+5％B
The elutriant that collection retention time is 100～155min can obtain Sostatin solution.
6. preparation method as claimed in claim 5, is characterized in that, in described anti-phase purifying, flow velocity is 200mL/min; In described anti-phase desalination, flow velocity is 200mL/min.
7. preparation method as claimed in claim 1, is characterized in that, the filling condition of described high performance liquid phase reverse-phase chromatography is as follows: filler is Agilent PLRP-S styrene diethylene benzene copoly mer, aperture 10nm, particle diameter 10 μ m, dress column density 0.33g/mL, post is pressed as 650psi.
8. a preparation method for Sostatin acetate, it comprises the steps: that the Sostatin that the preparation method described in any one in claim 1～7 is obtained mixes with acetic acid.
9. preparation method as claimed in claim 8, is characterized in that, after described mixing finishes, also carries out concentrating under reduced pressure, lyophilize.
10. preparation method as claimed in claim 9, is characterized in that, the pressure of described concentrating under reduced pressure is-0.15～-0.05MPa, and the temperature of described concentrating under reduced pressure is 25～35 DEG C.
The 11. Sostatin acetate that do not contain trifluoroacetic acid that made by the preparation method described in any one in claim 8～10.
CN201410228795.1A 2014-05-27 2014-05-27 Octreotide, the preparation method of octreotide acetate Active CN103965291B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410228795.1A CN103965291B (en) 2014-05-27 2014-05-27 Octreotide, the preparation method of octreotide acetate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410228795.1A CN103965291B (en) 2014-05-27 2014-05-27 Octreotide, the preparation method of octreotide acetate

Publications (2)

Publication Number Publication Date
CN103965291A true CN103965291A (en) 2014-08-06
CN103965291B CN103965291B (en) 2016-09-21

Family

ID=51235339

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410228795.1A Active CN103965291B (en) 2014-05-27 2014-05-27 Octreotide, the preparation method of octreotide acetate

Country Status (1)

Country Link
CN (1) CN103965291B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104672308A (en) * 2014-12-23 2015-06-03 青岛康原药业有限公司 Method for preparing vasopressin tannate
CN106632612A (en) * 2017-01-04 2017-05-10 陕西慧康生物科技有限责任公司 Low-cost purifying method of osteogenic growth peptide
CN106749528A (en) * 2017-01-03 2017-05-31 上海上药第生化药业有限公司 A kind of preparation method of Octreotide
CN107778351A (en) * 2016-08-25 2018-03-09 成都圣诺生物制药有限公司 A kind of method of full synthesis in solid state Octreotide

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1355173A (en) * 2000-11-29 2002-06-26 中国人民解放军军事医学科学院毒物药物研究所 Liquid-phase synthesis process of octreotide acetate
CN1569890A (en) * 2004-04-30 2005-01-26 长春力尔凡药业有限公司 Solid-phase synthesis process of octreotide acetate
WO2006041945A2 (en) * 2004-10-04 2006-04-20 Novetide, Ltd. A counterion exchange process for peptides
CN103102390A (en) * 2011-11-09 2013-05-15 杭州华津允上医药有限公司 Preparation method for octreotide

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1355173A (en) * 2000-11-29 2002-06-26 中国人民解放军军事医学科学院毒物药物研究所 Liquid-phase synthesis process of octreotide acetate
CN1569890A (en) * 2004-04-30 2005-01-26 长春力尔凡药业有限公司 Solid-phase synthesis process of octreotide acetate
WO2006041945A2 (en) * 2004-10-04 2006-04-20 Novetide, Ltd. A counterion exchange process for peptides
CN103102390A (en) * 2011-11-09 2013-05-15 杭州华津允上医药有限公司 Preparation method for octreotide

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104672308A (en) * 2014-12-23 2015-06-03 青岛康原药业有限公司 Method for preparing vasopressin tannate
CN107778351A (en) * 2016-08-25 2018-03-09 成都圣诺生物制药有限公司 A kind of method of full synthesis in solid state Octreotide
CN106749528A (en) * 2017-01-03 2017-05-31 上海上药第生化药业有限公司 A kind of preparation method of Octreotide
CN106632612A (en) * 2017-01-04 2017-05-10 陕西慧康生物科技有限责任公司 Low-cost purifying method of osteogenic growth peptide
CN106632612B (en) * 2017-01-04 2020-05-19 陕西慧康生物科技有限责任公司 Low-cost purification method of osteogenic growth peptide

Also Published As

Publication number Publication date
CN103965291B (en) 2016-09-21

Similar Documents

Publication Publication Date Title
CN103980351B (en) The preparation method of pitressin, pitressin tannate
CN104672308A (en) Method for preparing vasopressin tannate
CN103965291A (en) Method for preparing octreotide and octreotide acetate
CN112661815B (en) Method for purifying Tirzepatide
CN101584853B (en) Earthworm protein polypeptide preparation
CN106699851B (en) A kind of preparation method of pitressin deamidation impurity
CN112724241A (en) Purification method of abamectin
WO2020224580A1 (en) Refining method for vasopressin
CN106518978B (en) Preparation method of vasopressin [4-Glu,5-Asp ]
CN109438561A (en) A kind of purification process of Triptorelin
WO2020114002A1 (en) Method for purifying polypeptide similar to glp-1
CN106749541A (en) A kind of preparation method of pitressin [5 Asp]
CN103965296A (en) Method for preparing angiotensin and angiotensin acetate
CN105223296B (en) The purification process of a kind of polypeptide
CN105153284B (en) Method for purifying linaclotide
CN105693844A (en) Preparation method of gonadotrophin-releasing hormone analogue acetate
CN106518975B (en) A kind of preparation method of pitressin
CN113624898B (en) Purification method of chiral analgesic polypeptide medicine
CN112279895B (en) Preparation method of chemically synthesized acidic polypeptide
CN109942686A (en) A kind of refining methd of pitressin acetylation impurity
CN106749528A (en) A kind of preparation method of Octreotide
CN111848777A (en) Method for purifying somaglutide
CN114685615B (en) Purification method of triptorelin acetate polypeptide crude product
CN106749540B (en) Preparation method of vasopressin [4-Glu ]
CN110078796B (en) Method for refining oxytocin [4-Glu,5-Asp ] impurity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee
CP01 Change in the name or title of a patent holder

Address after: 200240 Shanghai city Minhang District Jianchuan Road No. 1317

Patentee after: Add medicine to the first biochemical pharmaceutcal corporation, Ltd in Shanghai

Address before: 200240 Shanghai city Minhang District Jianchuan Road No. 1317

Patentee before: Shanghai No.1 Biochemical & Pharmaceutical Co., Ltd.